Skip to main content
. 2022 Jul 16;195(1):65–74. doi: 10.1007/s10549-022-06643-y

Fig. 2.

Fig. 2

A Pharmacokinetic profile of endoxifen steady-state concentrations (n = 301) stratified based on CYP2D6 phenotype, median (IQR). PM poor metabolizer 7.6 (6.6–9.0); IM, intermediate metabolizer 21.5 (13.9–30.2); NM, normal metabolizer 31.5 (22.9–40.3). B Pharmacokinetic profile of endoxifen steady-state concentrations (n = 301) stratified on CYP2D6 activity score (AS) based on their allele combination, median (IQR). PM/PM 7.6 (6.6–9.0), IM/PM 11.2 (9.1–12.4), IM/IM 15.2 (13.3–24.1), NM/PM 26.6 (19.0–32.8), NM/IM 26.6 (19.2–32.8), NM/NM 34.1 (25.6–44.3)